DITROPAN XL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ditropan Xl, and when can generic versions of Ditropan Xl launch?
Ditropan Xl is a drug marketed by Janssen Pharms and is included in one NDA.
The generic ingredient in DITROPAN XL is oxybutynin chloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ditropan Xl
A generic version of DITROPAN XL was approved as oxybutynin chloride by TEVA PHARMS USA on November 14th, 1988.
Summary for DITROPAN XL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 21 |
| Patent Applications: | 1,693 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DITROPAN XL |
| DailyMed Link: | DITROPAN XL at DailyMed |
Recent Clinical Trials for DITROPAN XL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Brigham and Women's Hospital | Phase 2 |
| Kessler Foundation | Phase 2 |
| National Institute on Disability, Independent Living, and Rehabilitation Research | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for DITROPAN XL
US Patents and Regulatory Information for DITROPAN XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | DITROPAN XL | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 020897-001 | Dec 16, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Janssen Pharms | DITROPAN XL | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 020897-002 | Dec 16, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Janssen Pharms | DITROPAN XL | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 020897-003 | Jun 22, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DITROPAN XL
International Patents for DITROPAN XL
See the table below for patents covering DITROPAN XL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 3417113 | ⤷ Try a Trial | |
| Australia | 5639296 | ⤷ Try a Trial | |
| Canada | 2218714 | FORME GALENIQUE CONTENANT DE L'OXYBUTYNINE (DOSAGE FORM COMPRISING OXYBUTYNIN) | ⤷ Try a Trial |
| Italy | 1285345 | FORMA DI DOSAGGIO COMPRENDENTE OSSIBUTININA | ⤷ Try a Trial |
| United Kingdom | 2318055 | Dosage form comprising oxybutynin | ⤷ Try a Trial |
| France | 2734483 | FORME D'ADMINISTRATION PHARMACEUTIQUE COMPRENANT DE L'OXYBUTYNINE | ⤷ Try a Trial |
| Japan | H0575725 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
